Overview

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment

Status:
Not yet recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo/active-controlled study. About 285 subjects undergoing elective abdominal operation under general anesthesia are planned to be enrolled and randomized into the HSK21542 group (95 subjects), tramadol group (95 subjects), and placebo group (95 subjects).

Phase:

Phase 3

Details

Lead Sponsor:

Haisco Pharmaceutical Group Co., Ltd.

Treatments:

Tramadol